NurExone Reports First Quarter 2023 Financial Results and Provides Corporate Update
As the Company scales, NurExone intends to continue expanding its patent portfolio in order to strengthen its competitive moat.
- As the Company scales, NurExone intends to continue expanding its patent portfolio in order to strengthen its competitive moat.
- Research and development expenses were US$0.37 million in the first quarter of 2023, compared to US$0.28 million in the same quarter in 2022.
- Financial (income) expenses were (US$0.01) million in the first quarter of 2023, compared to US$0.09 million in the same period in 2022.
- Net loss was US$0.70 million in the first quarter of 2023, compared to a net loss of US$2.31 million in the first quarter of 2022.